1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
Delayed Japan Exchange  -  02:00 2022-08-16 am EDT
3865.00 JPY   -0.08%
08/15CHUGAI PHARMACEUTICAL : Obtains Regulatory Approval for Osteoporosis Treatment Edirol Tablet
PU
08/11Chugai Pharmaceutical Co., Ltd. - Anti-C5 Recycling Antibody Crovalimab Obtains Priority Review in China for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
AQ
08/10Roche's Rare Blood Disease Drug Wins Priority Review Tag In China
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Galderma Announces Topline Results of OLYMPIA 2 Study Evaluating Nemolizumab in Prurigo Nodularis

06/23/2022 | 08:20am EDT

TOKYO - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Galderma issued a press release on June 22 regarding positive topline results of a phase III clinical study, in prurigo nodularis (OLYMPIA 2) for the humanized anti-human IL-31 receptor A monoclonal antibody nemolizumab, created by Chugai. Clinical development of nemolizumab outside Japan has been conducted by Galderma.

Please refer to the link below for details of the press release:

Galderma announces positive data from phase III trial, demonstrating efficacy and safety of nemolizumab in patients with prurigo nodularis https://www.galderma.com/news/galderma-announces-positive-data-phase-iii-trial-demonstrating-efficacy-and-safety-nemolizumab

Contact:

Media

Chugai Pharmaceutical Co., Ltd.

Media Relations Group

Corporate Communications Dept.

Tomoko Shimizu

Tel: +81-3-3273-0881

E-mail: pr@chugai-pharm.co.jp

(C) 2022 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD -0.08% 3865 Delayed Quote.3.56%
ROCHE HOLDING AG 0.92% 317.9 Delayed Quote.-16.14%
All news about CHUGAI PHARMACEUTICAL CO., LTD
08/15CHUGAI PHARMACEUTICAL : Obtains Regulatory Approval for Osteoporosis Treatment Edirol Tabl..
PU
08/11Chugai Pharmaceutical Co., Ltd. - Anti-C5 Recycling Antibody Crovalimab Obtains Priorit..
AQ
08/10Roche's Rare Blood Disease Drug Wins Priority Review Tag In China
MT
08/10CHUGAI PHARMACEUTICAL : Anti-C5 Recycling Antibody Crovalimab Obtains Priority Review in C..
PU
08/09Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litig..
AQ
08/08Chugai Pharmaceutical Co., Ltd. - Maruho Launched in Japan the Anti-IL-31 Receptor a Hu..
AQ
08/08CHUGAI PHARMACEUTICAL : Notice of the Settlement of Patent Infringement Litigation in the ..
PU
08/08Roche's Chugai Unit Launches Skin Disease Drug in Japan
MT
08/07CHUGAI PHARMACEUTICAL : Maruho Launched in Japan the Anti-IL-31 Receptor A Humanized Monoc..
PU
07/27Nikkei 225 Up 0.2% Ahead of Federal Reserve Announcement
MT
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD
More recommendations
Financials
Sales 2022 1 191 B 8 952 M 8 952 M
Net income 2022 347 B 2 609 M 2 609 M
Net cash 2022 518 B 3 895 M 3 895 M
P/E ratio 2022 18,3x
Yield 2022 2,06%
Capitalization 6 363 B 47 815 M 47 815 M
EV / Sales 2022 4,91x
EV / Sales 2023 5,38x
Nbr of Employees 7 664
Free-Float 38,0%
Chart CHUGAI PHARMACEUTICAL CO., LTD
Duration : Period :
Chugai Pharmaceutical Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 3 868,00 JPY
Average target price 4 617,50 JPY
Spread / Average Target 19,4%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Manager-Pharmaceutical Business Strategy Office
Osamu Okuda Manager-Life Cycle Management II
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD3.56%47 815
JOHNSON & JOHNSON-2.91%434 603
ELI LILLY AND COMPANY13.66%292 730
PFIZER, INC.-15.75%281 235
ROCHE HOLDING AG-16.91%275 562
ABBVIE INC.5.09%252 131